Replies to post #137254 on Biotech Values

[genisi]

Shire's capacity has improved as its new manufacturing facility in Lexington received EMA approval for the production of Vpriv.

This additional capacity will allow Shire to significantly increase global supply of VPRIV and provides additional manufacturing flexibility. The EMA approval is also a critical first step in releasing further capacity for the manufacturing of REPLAGAL® (agalsidase alfa) at Shire’s Alewife facility. The new facility increases bioreactor capacity from 1000 to 8000L

http://www.shire.com/shireplc/en/investors/investorsnews/irshirenews?id=561